Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.27 - $11.9 $1,134 - $49,980
-4,200 Reduced 13.95%
25,900 $7,000
Q3 2022

Nov 14, 2022

SELL
$0.51 - $10.4 $8,007 - $163,280
-15,700 Reduced 34.28%
30,100 $15,000
Q2 2022

Aug 15, 2022

SELL
$0.57 - $1.22 $20,577 - $44,042
-36,100 Reduced 44.08%
45,800 $26,000
Q1 2022

May 16, 2022

SELL
$0.93 - $1.29 $22,878 - $31,734
-24,600 Reduced 23.1%
81,900 $106,000
Q4 2021

Feb 14, 2022

SELL
$1.14 - $1.58 $18,810 - $26,070
-16,500 Reduced 13.41%
106,500 $121,000
Q3 2021

Nov 15, 2021

SELL
$1.39 - $2.1 $1.04 Million - $1.57 Million
-748,200 Reduced 85.88%
123,000 $188,000
Q2 2021

Aug 16, 2021

BUY
$1.56 - $2.26 $1.17 Million - $1.69 Million
747,900 Added 606.57%
871,200 $1.73 Million
Q1 2021

May 17, 2021

BUY
$1.77 - $2.98 $218,241 - $367,434
123,300 New
123,300 $227,000

About Hepion Pharmaceuticals, Inc.


  • Ticker HEPA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,229,600
  • Market Cap $51.8M
  • Description
  • Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...
More about HEPA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.